查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870121

化療引起的噁心嘔吐治療市場（按藥物類別、給藥途徑、治療類型、通路、最終用戶、嘔吐風險和患者年齡層分類）—全球預測，2025-2032年

Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，化療引起的噁心和嘔吐治療市場將成長至 52.8 億美元，複合年成長率為 6.74%。

關鍵市場統計數據
基準年 2024 31.3億美元
預計年份：2025年 33.4億美元
預測年份 2032 52.8億美元
複合年成長率 (%) 6.74%

這是一份重點突出的高管入門指南，闡述了當代臨床挑戰、以患者為中心的治療結果以及塑造止吐治療路徑的戰略要務。

化療引起的噁心和嘔吐仍然是接受細胞毒性藥物和標靶治療的患者最主要的副作用之一。臨床醫生在選擇止吐方案時，總是會考慮療效、耐受性和患者的生活品質，而支付方和醫療服務提供者則會仔細權衡成本、可及性和依從性等因素。同時，藥理學、輔助支持治療和給藥方式的進步正在重塑治療選擇和臨床路徑。

識別臨床實務、藥物研發、報銷模式和病患參與的變革性變化，以重新定義止吐治療服務。

化療引起的噁心嘔吐治療領域正經歷一系列變革，這些變革影響著臨床實踐、研發重點以及支付者的決策。在臨床上，人們越來越重視預防而非僅僅關注症狀的偶發性控制，這推動了多機制治療方案的採用，並加強了指南指導下的治療。這些變化反映了人們對催吐途徑的更深入了解，以及對能夠最大限度減少後續併發症和非計劃醫療資源利用的治療方案的日益青睞。

2025年美國關稅調整的累積經濟、政策和供應鏈影響及其對止吐療法可及性的影響

關稅調整等政策變化會對藥品供應鏈、採購慣例以及最終的臨床用藥產生連鎖反應。 2025年美國關稅調整導致進口成本和行政流程複雜度發生變化，並波及製造商、合約經銷商和機構採購商。這些影響不僅體現在直接採購環節，也體現在關鍵支持性治療藥物的策略採購決策和庫存管理實務。

可操作的細分分析揭示了藥物類別、給藥途徑、治療方法、分銷管道、最終用戶、嘔吐風險和年齡層如何影響臨床選擇。

細緻的細分觀點揭示了影響臨床和操作偏好的因素，這些因素涵蓋藥物類別、給藥途徑、治療類型、分銷管道、最終用戶、噁心風險和患者年齡。在藥物類別選擇方面，受體標靶藥物在中高風險止吐方案的預防策略中佔據主導地位。在5-HT3受體拮抗劑中，GranisetronOndansetron、昂丹司瓊、Palonosetron和雷莫司瓊因其起效時間、持續時間和耐受性而受到關注，而地塞米松和Methylprednisolone等皮質類固醇仍作為基礎輔助性治療。多巴胺受體拮抗劑在搶救治療和特定適應症中仍然有效，其中甲氧氯普胺和丙氯拉嗪保留了其獨特的臨床作用。 NK1受體拮抗劑，包括Aprepitant和福沙吡坦，是高風險通訊協定聯合治療的關鍵藥物。

影響藥品取得、處方趨勢、監管演變和供應韌性的區域趨勢：美洲、歐洲/中東/非洲和亞太地區

區域趨勢對監管方式、藥品取得途徑和供應穩定性有顯著影響。在美洲，醫療衛生系統高度重視實證預防和整合式診療路徑，以促進患者遵循指引建議的治療方案。完善的採購系統為合約簽訂和庫存策略提供支持，從而穩定藥品取得。在歐洲、中東和非洲地區，監管的多樣性和報銷模式的差異導致了不同的藥品獲取途徑，一些地區優先考慮集中採購，而另一些地區則依賴區域性處方集決策，這影響了新藥及其組合藥物的上市速度。

競爭情報重點關注領先的止吐藥物開發商的創新、夥伴關係、產品線定位和商業化策略

止吐藥領域的企業競爭取決於漸進式創新、產品系列的廣度、夥伴關係策略和商業執行力等因素的綜合作用。如果差異化配方、緩釋性特性或新型給藥系統能夠轉化為醫療機構依從性或營運效率的顯著提升，那麼擁有這些特性的研發企業就能獲得相對優勢。同樣重要的是，透過策略聯盟可以擴大分銷管道、共同開發聯合治療，或整合用於監測患者症狀和依從性的互補型數位健康工具。

旨在改善臨床療效、增強供應韌性、最佳化定價和提升病患服務的實用策略建議

致力於提升治療效果和營運韌性的領導者應制定優先行動計劃，協調臨床、商業和供應鏈目標。首先，應在臨床環境中統一預防通訊協定，最大限度地減少治療方法選擇上的差異，並確保嘔吐風險分層能夠促進實踐的一致性。統一臨床路徑可以減少不必要的實踐差異，並支援可預測的採購和庫存計劃。

為確保研究結果的可靠性，我們採用了一套全面的調查方法：涵蓋資料收集、資訊來源三角驗證、分析架構、檢驗程序以及專家參與等各個面向。

本報告的分析整合了多項一手和二手研究資料，以確保研究結果的三角驗證和檢驗。資料收集包括對同儕審查文獻、監管文件和臨床指南的系統性回顧，以及對臨床醫生、藥房部門主管、供應鏈經理和行業高管的結構化訪談。這種混合方法能夠同時捕捉定量模式和定性背景訊息，從而為決策提供依據。

策略要務、持續挑戰和發展路徑的關鍵整合，對於改善止吐治療中的患者療效和營運韌性至關重要。

這項綜合分析突顯了持續存在的挑戰，包括：根據嘔吐風險和患者狀況匹配治療方法方案、主動管理供應鏈韌性以及產生真實世界證據以促進廣泛應用。持續存在的挑戰還包括協調臨床醫生、支付方和採購機構相關利益者的獎勵，以及確保在不同的地理環境中公平地獲得治療。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 開發長效神經激肽-1受體拮抗劑以改善化療引起的噁心和嘔吐（CINV）的治療
  • 整合數位健康監測工具，用於個人化預防化療引起的噁心和嘔吐 (CINV) 並支持用藥依從性
  • 針對多種化療引起的噁心嘔吐（CINV）路徑並提高給藥便利性的口服固定劑量複方製劑的出現，為患者帶來了便利。
  • 擴大大麻素類治療方法難治化療引起的噁心和嘔吐的研究
  • 藥物基因體學分析在為化療患者個體化製定止吐方案方面正受到越來越多的關注。
  • 在致吐性極強的化療通訊協定中，擴大採用指引推薦的四聯止吐療法
  • 開發一種長效型經皮止吐貼劑，以提高門診病患的依從性
  • 評估奧Olanzapine輔助治療預防化療遲發性噁心嘔吐的臨床試驗數量迅速增加
  • 過渡到低成本的非專利止吐藥製劑有助於促進市場競爭，並降低治療成本。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章化療引起的噁心和嘔吐治療藥物市場

  • 5-HT3受體拮抗劑
    • Granisetron
    • Ondansetron
    • Palonosetron
    • 拉莫塞特龍
  • 皮質類固醇
    • 地塞米松
    • Methylprednisolone
  • 多巴胺受體拮抗劑
    • 甲氧氯普胺
    • 丙氯拉嗪
  • NK1受體拮抗劑
    • Aprepitant
    • 福沙普利坦

第9章化療引起的噁心嘔吐治療市場（依給藥途徑分類）

  • 靜脈注射
  • 口服

第10章化療引起的噁心嘔吐治療市場（依治療類型分類）

  • 聯合治療
    • 雙重療法
      • 5-HT3受體拮抗劑和NK1受體拮抗劑
      • 5-HT3受體拮抗劑和類固醇
      • NK1受體拮抗劑和類固醇
    • 三聯療法
  • 單藥治療

第11章化療引起的噁心嘔吐治療市場（按通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章化療引起的噁心和嘔吐治療市場（按最終用戶分類）

  • 居家醫療環境
  • 醫院
  • 專科診所

第13章化療引起的噁心嘔吐治療市場（依嘔吐風險分類）

  • 高風險
  • 低風險
  • 輕度風險
  • 中等風險

第14章 依患者年齡層分類的化療引起的噁心和嘔吐治療市場

  • 成人
  • 兒童

第15章 各地區化療引起的噁心嘔吐治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章化療引起的噁心嘔吐治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國化療引起的噁心嘔吐治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Eisai Co., Ltd.
    • Helsinn Healthcare SA
    • GlaxoSmithKline plc
    • Heron Therapeutics, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Mylan NV
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-3204321AF679

The Chemotherapy Induced Nausea & Vomiting Treatment Market is projected to grow by USD 5.28 billion at a CAGR of 6.74% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.13 billion
Estimated Year [2025] USD 3.34 billion
Forecast Year [2032] USD 5.28 billion
CAGR (%) 6.74%

A focused executive primer defining contemporary clinical challenges, patient-centric outcomes, and strategic imperatives shaping antiemetic therapy pathways

Chemotherapy induced nausea and vomiting remains one of the most consequential adverse effects experienced by patients undergoing cytotoxic or targeted oncology therapies. Clinicians continue to balance efficacy, tolerability, and patient quality of life when selecting antiemetic regimens, while payers and providers navigate cost, access, and adherence considerations. In parallel, advances in pharmacology, adjunctive supportive care, and administration modalities are reshaping therapeutic choices and clinical pathways.

The modern treatment landscape increasingly emphasizes individualized approaches that account for emetic risk, comorbidities, and patient-specific factors such as age and prior response to antiemetics. As a result, stakeholders across clinical practice, pharmacy operations, and commercial strategy require clear, evidence-informed perspectives on drug classes, regimen composition, and delivery settings. This introduction consolidates core themes that persistently influence therapeutic decision-making and frames the subsequent analysis in terms of clinical imperatives, stakeholder incentives, and operational constraints.

Moving forward, the report navigates the intersection of clinical innovation, regulatory developments, and supply chain dynamics. It highlights how incremental improvements in antiemetic efficacy, shifts in administration preference, and evolving care delivery models collectively affect patient experience and institutional readiness. The intent here is to set a pragmatic foundation that aligns clinician priorities with organizational objectives, enabling informed choices that protect patients' quality of life while maintaining operational viability.

Identifying transformative shifts across clinical practice, drug development, reimbursement models, and patient engagement that are redefining antiemetic care delivery

The treatment landscape for chemotherapy induced nausea and vomiting is undergoing a sequence of transformative shifts that touch clinical practice, development priorities, and payer decision-making. Clinically, a stronger emphasis on prevention ahead of breakthrough management has driven adoption of multi-mechanistic regimens and reinforced guideline-driven care. These shifts reflect improved understanding of emetic pathways and a growing preference for regimens that minimize downstream morbidity and unplanned care utilization.

From a development perspective, pharmaceutical strategies prioritize formulations and combinations that enhance adherence and enable outpatient administration. This trend is complemented by innovation in oral agents and extended half-life formulations that reduce dosing complexity. Simultaneously, regulatory emphasis on real-world effectiveness and patient-reported outcomes is shaping trial design and post-approval evidence generation, encouraging sponsors to embed pragmatic endpoints that resonate with clinicians and payers alike.

Payer and provider systems are converging on value-based criteria that stress both clinical outcomes and total cost of care. Consequently, stakeholders are reassessing formulary placement and contracting strategies to favor therapies that demonstrate consistent prophylactic benefit. At the same time, patient engagement initiatives and digital health tools are being deployed to improve adherence and symptom reporting, which helps clinicians titrate therapy more precisely and detect breakthrough nausea earlier.

Taken together, these shifts are not isolated; they are mutually reinforcing. Improved agents enable ambulatory care models, which in turn change distribution and procurement practices. As the landscape evolves, organizations that integrate clinical, commercial, and operational perspectives will be best positioned to convert scientific advances into sustained improvements in patient experience.

Cumulative economic, policy and supply chain ramifications of the 2025 United States tariff adjustments and effects on antiemetic treatment access

Policy changes such as tariff adjustments can have a cascade of effects across pharmaceutical supply chains, procurement practices, and ultimately clinical access. United States tariff changes implemented in 2025 introduced modifications to import costs and administrative complexity that ripple through manufacturers, contract distributors, and institutional buyers. These effects manifested not only in direct procurement operations but also in strategic sourcing decisions and inventory management practices for critical supportive care medicines.

In practical terms, procurement teams faced shorter planning horizons and increased emphasis on local sourcing where feasible, prompting some health systems to diversify supplier relationships. Manufacturers and contract distributors responded by reassessing production footprints, increasing engagement with domestic contract manufacturing organizations, and in some cases prioritizing higher-margin formulations. These operational responses aimed to mitigate exposure to tariff-related cost shifts and to maintain continuity of supply.

Clinicians and pharmacy leaders adapted by refining ordering cadence, reinforcing stock rotation policies, and expanding therapeutic substitution protocols to preserve continuity of care. At the same time, payers and procurement entities examined contractual terms and rebate structures to ensure predictable access to guideline-recommended regimens. Importantly, these adjustments were not uniformly disruptive; institutions with advanced supply chain analytics and close manufacturer partnerships were able to maintain steady access with minimal clinical impact.

Overall, the policy environment in 2025 underscored the importance of supply chain visibility, diversified sourcing strategies, and proactive engagement between manufacturers and health systems. These lessons have durability beyond immediate policy cycles and should inform long-term planning for essential supportive care therapies.

Actionable segmentation insights revealing how drug classes, administration routes, therapy regimens, distribution channels, end users, emetic risk and age cohorts drive clinical choice

A nuanced segmentation lens reveals the drivers of clinical choice and operational preference across drug class, route, therapy type, distribution, end user, emetic risk, and patient age. When considering drug class selection, receptor-targeted agents dominate prophylactic strategies for moderately and highly emetogenic regimens; within 5-HT3 receptor antagonists, practitioners weigh differences among granisetron, ondansetron, palonosetron and ramosetron based on onset, duration and tolerability, while corticosteroids such as dexamethasone and methylprednisolone continue to be foundational adjuncts. Dopamine receptor antagonists remain relevant for rescue and select indications, with metoclopramide and prochlorperazine retained for their clear clinical roles, and NK1 receptor antagonists, including aprepitant and fosaprepitant, are integral to combination regimens for high-risk protocols.

Route of administration is a critical operational consideration; the choice between intravenous and oral delivery shapes inpatient workflows, outpatient infusion center throughput, and home care feasibility. Intravenous administration offers immediate bioavailability and is often favored in acute settings, while oral options support ambulatory care and greater patient convenience. Treatment strategy is further refined through therapy type selection, where monotherapy may be appropriate for low risk scenarios but combination therapy-either dual or triple regimens-dominates prophylaxis for higher emetic risk. Dual regimens commonly combine 5-HT3 and NK1 agents, 5-HT3 agents with steroids, or NK1 agents with steroids, each pairing chosen to target complementary pathways and maximize prophylactic benefit.

Distribution channel considerations influence accessibility and adherence. Hospital pharmacies play a central role for inpatient and infusion center needs, retail pharmacies support community dispensing, and online pharmacies are increasingly used for repeat dosing and home delivery models. End user contexts-home care settings, hospitals, and specialty clinics-each impose distinct constraints and opportunities: home care demands simplified regimens and clear patient education materials, hospitals require integration with electronic prescribing and formulary controls, and specialty clinics prioritize regimen efficacy aligned with oncologic protocols.

Emetic risk stratification-classified as high, moderate, low or minimal-remains the primary clinical axis around which regimen intensity is determined, and patient age groups, whether adult or pediatric, require tailored dosing, formulation selection and tolerability considerations. Pediatric patients often need age-appropriate formulations and dosing strategies that reduce administration burden, whereas adult cohorts accommodate a broader range of oral and intravenous options. In sum, rigorous segmentation supports precise therapeutic alignment: selecting the appropriate agent and regimen for a patient's emetic risk and care setting while accounting for distribution and age-related considerations leads to better adherence and clinical outcomes.

Regional dynamics shaping access, prescribing trends, regulatory evolution, and supply resiliency across Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert substantial influence over regulatory approaches, access pathways, and supply resilience. In the Americas, health systems display a strong emphasis on evidenced-based prophylaxis and integrated care pathways that promote adherence to guideline-recommended regimens; procurement sophistication supports contracting arrangements and inventory strategies that stabilize access. Across Europe, Middle East & Africa, regulatory heterogeneity and variable reimbursement models create differentiated pathways to access, with some jurisdictions prioritizing centralized procurement and others relying on localized formulary decision-making, which impacts how quickly new formulations or combinations are adopted.

In Asia-Pacific, rapid expansion of oncology services and growing emphasis on ambulatory care are accelerating demand for oral and long-acting antiemetic options. Regional manufacturing footprints and supplier diversification in this area also influence product availability and pricing dynamics. Across all regions, localized clinical practice patterns, national guideline endorsements, and health system procurement capabilities drive how therapies are implemented in practice. For example, countries with robust outpatient oncology infrastructure are more likely to favor oral regimens that support home administration, whereas regions with constrained outpatient capacity may rely more heavily on infusion-based strategies.

Supply chain considerations differ by region as well; jurisdictions with established domestic production capacity exhibit greater resilience to import disruptions, while those reliant on international suppliers are more sensitive to policy shifts and logistical constraints. Clinicians and health system leaders must therefore calibrate procurement strategies, formulary decisions, and patient education efforts to local realities, leveraging regional partnerships and cross-border collaboration where possible to maintain continuity of care and equitable access.

Competitive intelligence highlighting innovation, partnerships, pipeline positioning and commercialization strategies of major antiemetic developers

Competitive dynamics among companies in the antiemetic space are defined by a combination of incremental innovation, portfolio breadth, partnership strategies, and commercialization execution. Developers with differentiated formulations, extended-release profiles, or novel delivery systems gain relative advantage when those attributes translate into measurable adherence improvements or workflow efficiencies for providers. Equally important are strategic alliances that broaden distribution reach, enable co-development of combination approaches, or integrate adjunctive digital health tools to monitor patient symptoms and adherence.

Generic manufacturers and specialty pharmaceutical companies play complementary roles: generics provide price-competitive access for established agents, while specialty firms focus on next-generation formulations, combination products, or indications that extend prophylactic coverage. Pipeline activity often centers on combination packaging, novel oral formulations that simplify dosing, and improvements in tolerability, reflecting an industry focus on reducing the clinical burden of nausea while enabling care in ambulatory and home settings.

Commercial strategy matters; companies that deploy targeted clinician education, real-world evidence generation, and value communications aligned with payer priorities achieve stronger formulary positioning. Moreover, manufacturing resilience and supply chain transparency are critical differentiators, as buyers increasingly demand predictable supply and collaborative contingency planning. Ultimately, firms that integrate clinical evidence, operational reliability, and clear value propositions are best positioned to influence treatment protocols and capture sustained clinical trust.

Practical strategic recommendations for leaders to improve clinical outcomes, shore up supply resilience, refine pricing and enhance patient services

Leaders seeking to strengthen therapeutic impact and operational resilience should pursue a set of prioritized actions that align clinical, commercial, and supply chain objectives. First, standardize prophylaxis protocols across care settings to minimize variability in regimen selection and ensure that emetic risk stratification drives consistent practice. Aligning clinical pathways reduces unwarranted practice variation and supports predictable procurement and inventory planning.

Second, diversify sourcing and build contractual mechanisms that ensure continuity of supply. Long-term supplier agreements, regional manufacturing partnerships, and flexible contracting terms help institutions respond to policy shifts and logistical disruptions. In parallel, enhance supply chain visibility through analytics that forecast consumption, monitor inventory levels in near real time, and alert stakeholders to potential constraints before they impact patient care.

Third, prioritize regimen simplification where clinically appropriate. Favoring formulations and combinations that reduce dosing complexity supports adherence in home care settings and decreases administration burden in outpatient infusion centers. Complement regimen optimization with robust patient education and digital adherence supports that improve symptom reporting and early intervention for breakthrough nausea.

Finally, invest in evidence generation that resonates with payers and clinicians. Real-world effectiveness studies, patient-reported outcome data, and comparative effectiveness analyses provide persuasive inputs for formulary discussions and guideline updates. By integrating these strategic initiatives-protocol standardization, supply diversification, regimen simplification, and targeted evidence generation-leaders can both elevate patient outcomes and reduce operational risk.

Comprehensive research methodology covering data collection, source triangulation, analysis frameworks, validation steps and expert engagement for robust insights

The analysis underpinning this report synthesizes multiple primary and secondary research streams to ensure triangulated and validated insights. Data collection combined systematic review of peer-reviewed literature, regulatory documentation, and clinical guidelines with structured interviews of clinicians, pharmacy leaders, supply chain managers, and industry executives. This mixed-methods approach enabled the capture of both quantitative patterns and qualitative context that inform decision-making.

Analytical frameworks included comparative regimen assessment, distribution channel mapping, and stakeholder impact analysis. These frameworks guided evaluation of drug classes, administration routes, and therapy types in relation to clinical outcomes and operational feasibility. Validation steps included cross-referencing interview findings with published guidelines and supply chain data, seeking convergence across independent sources to minimize bias and enhance reliability.

Expert engagement involved advisory consultations with clinicians and pharmacy directors to test assumptions and prioritize areas of operational risk. Where ambiguity emerged, targeted follow-up interviews and additional desk research were deployed to refine conclusions. Together, these methods produced a coherent evidence base that supports pragmatic recommendations and highlights where further bespoke research would add value.

Conclusive synthesis of strategic imperatives, enduring challenges and growth pathways to elevate patient outcomes and operational resilience in antiemetic care

The synthesis presented here underscores several enduring imperatives: therapies should be selected to match emetic risk and patient context; supply chain resilience must be actively managed; and evidence generation tailored to real-world practice is essential for broader adoption. Persistent challenges include aligning stakeholder incentives across clinicians, payers, and procurement entities, and ensuring equitable access across diverse regional contexts.

Opportunities are clear. Simplified regimens and patient-friendly formulations support the transition to ambulatory and home-based care models, while targeted evidence that emphasizes patient-reported outcomes can shift payer calculus toward broader coverage. Operationally, investments in predictive inventory analytics and supplier diversification reduce exposure to policy-driven disruptions and support continuous care delivery.

In closing, success will require coordinated action: clinical teams must standardize approaches based on risk stratification; procurement leaders must secure adaptable supply arrangements; and commercial teams must communicate value in terms that matter to clinicians and payers. By aligning these elements, organizations can achieve sustained improvement in patient experience and operational performance in the management of chemotherapy induced nausea and vomiting.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of long-acting neurokinin-1 receptor antagonists for improved CINV management
  • 5.2. Integration of digital health monitoring tools for personalized CINV prophylaxis and adherence support
  • 5.3. Emergence of oral fixed-dose combination antiemetics targeting multiple CINV pathways and improving dosing convenience
  • 5.4. Expansion of research on cannabinoid-based therapies for refractory chemotherapy induced nausea and vomiting
  • 5.5. Growing focus on pharmacogenomic profiling to tailor antiemetic regimens for individual chemotherapy patients
  • 5.6. Increasing adoption of guideline recommended quadruple antiemetic regimens in high emetogenic chemotherapy protocols
  • 5.7. Development of long-acting transdermal antiemetic patches to enhance patient compliance in outpatient settings
  • 5.8. Surge in clinical trials evaluating adjunctive olanzapine for prevention of delayed chemotherapy induced nausea and vomiting
  • 5.9. Shift towards low-cost generic antiemetic formulations driving market competition and therapy affordability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Drug Class

  • 8.1. 5-HT3 Receptor Antagonists
    • 8.1.1. Granisetron
    • 8.1.2. Ondansetron
    • 8.1.3. Palonosetron
    • 8.1.4. Ramosetron
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone
    • 8.2.2. Methylprednisolone
  • 8.3. Dopamine Receptor Antagonists
    • 8.3.1. Metoclopramide
    • 8.3.2. Prochlorperazine
  • 8.4. NK1 Receptor Antagonists
    • 8.4.1. Aprepitant
    • 8.4.2. Fosaprepitant

9. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Therapy Type

  • 10.1. Combination Therapy
    • 10.1.1. Dual Regimen
      • 10.1.1.1. 5-HT3 And NK1
      • 10.1.1.2. 5-HT3 And Steroid
      • 10.1.1.3. NK1 And Steroid
    • 10.1.2. Triple Regimen
  • 10.2. Monotherapy

11. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Chemotherapy Induced Nausea & Vomiting Treatment Market, by End User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Emetic Risk

  • 13.1. High
  • 13.2. Low
  • 13.3. Minimal
  • 13.4. Moderate

14. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Patient Age Group

  • 14.1. Adult
  • 14.2. Pediatric

15. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Merck & Co., Inc.
    • 18.3.2. Eisai Co., Ltd.
    • 18.3.3. Helsinn Healthcare SA
    • 18.3.4. GlaxoSmithKline plc
    • 18.3.5. Heron Therapeutics, Inc.
    • 18.3.6. Teva Pharmaceutical Industries Ltd.
    • 18.3.7. Sandoz International GmbH
    • 18.3.8. Mylan N.V.
    • 18.3.9. Dr. Reddy's Laboratories Ltd.
    • 18.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOS